HTR1A抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 30 μg, Lane 1-2: HT29 cells, Mouse brain tissue, Primary antibody: P10634(HTR1A Antibody) at dilution 1/1500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10634(HTR1A Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

The HTR1A antibody is a research tool designed to detect and analyze the 5-hydroxytryptamine (serotonin) receptor 1A (HTR1A), a G protein-coupled receptor (GPCR) critical in regulating serotonin-mediated signaling. Expressed widely in the central nervous system, particularly in the hippocampus, cortex, and raphe nuclei, HTR1A modulates mood, anxiety, cognition, and stress responses. Dysregulation of this receptor is linked to psychiatric disorders such as depression, anxiety, and schizophrenia.

HTR1A antibodies are typically developed using synthetic peptides or recombinant proteins from conserved regions of the receptor. They enable applications like Western blotting, immunohistochemistry, and flow cytometry to study receptor expression, localization, and interactions with ligands (e.g., SSRIs, antipsychotics). Specificity validation via knockout controls or blocking assays is essential to avoid cross-reactivity with related GPCRs.

These antibodies support investigations into HTR1A’s role in neural plasticity, drug mechanisms, and disease pathways. Recent studies also explore its peripheral functions in immune and cardiovascular systems. However, challenges persist in ensuring antibody reliability across species and experimental conditions. Advances in epitope mapping and monoclonal antibody engineering continue to refine HTR1A-targeted research, aiding therapeutic development for serotonin-related disorders.